Jilab Inc. is a privately owned spin-off company founded by prof. Jorma Isola (University of Tampere, Finland). Research and development of our products and services is based on academic research done at the Laboratory of Cancer Biology.
Our focus is currently in celiac disease drug trials. We have been performing contract services in several celiac disease drug trials (CELIM-NRCD-001, CELIM-RCD-002, Nexvax2-1004, Nexvax2-2006, GLUTEN FRIENDLY) since 2016. In addition to celiac disease, we have provided pathology services for Crohn’s Disease (PRV-6527) and Ulcerative Colitis (PRV-300) drug trials.
Our strategy is to provide high-quality products and services for Finnish and international customers. We adapt to the needs of our clients and offer comprehensive service packages. The service packages are always designed together with the client to ensure that all needs and requirements are met. We use our accumulated experience and skills to our advantage and always aim to improve quality of our products and services.
Quality Management System
Jilab’s operations are regulated by quality management protocols. The quality management system conforms with all the requirements of ISO 17025:2017 standard.
Data Protection Regulation